Skip to main content

Global - branding

Atopic Dermatitis Seborrheic Dermatitis Plaque Psoriasis

Global - Mobile Menu

For U.S. Healthcare Professionals Only

ZORYVE Cream ZORYVE Foam

Pharmacy Locator

Atopic Dermatitis Seborrheic Dermatitis Plaque Psoriasis

MENU

For U.S. Healthcare Professionals Only

ZORYVE Cream ZORYVE Foam

Visit Patient Site

Connect With Us

Pharmacy Locator

Global - Main Navigation

Home
FOAM & CREAM FORMULATIONS
Patient Access Support
Resources
Connect With Us
Visit patient site

Not a steroid. No boxed warning

Connect with Us

CONTACT US
TO GET MORE
INFORMATION

Not a steroid. No boxed warning

Simple once-daily treatment

Simple once-daily treatment

ZORYVE (roflumilast) Cream 0.05%, ZORYVE (roflumilast) Cream 0.15%, ZORYVE (roflumilast) Cream 0.3%, and ZORYVE (roflumilast) Topical Foam 0.3%

global - Webform

Check off your selection(s) and complete the form below to receive your requested resources.

I'm looking for...

Samples

Medical information - Request a Medical Science Liaison

Patient access support - Request a Patient Access Manager

Materials/Resources for my practice

Please select at least one option.

All fields required unless otherwise noted.

Practitioner First Name

Practitioner Last Name

Credentials

MD

DO

NP

PA

Please select at least one option.

Specialty

Dermatology

Pediatric Dermatology

Allergy & Immunology

Primary Care

Pediatrics

Other

Please select at least one option

NPI Number (optional)

Email Address

Office Address

Suite Number (optional)

City

State

ZIP Code

Condition(s) interested in treating

Atopic Dermatitis

Plaque Psoriasis

Seborrheic Dermatitis

Please select at least one option.

I agree to receive occasional information from Arcutis Biotherapeutics about their products, services, programs, and/or other marketing information and agree to let Arcutis Biotherapeutics use the contact information provided for this purpose. I understand I can opt out of receiving these email communications at any time by selecting “unsubscribe” in the footer of the email. For more information, please see the Arcutis Privacy Notice and HCP Notice at Collection.

terms

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

By clicking submit, I acknowledge that Arcutis will collect, use, and disclose my personal information in accordance with the Arcutis Privacy Notice.

IMPORTANT SAFETY INFORMATION

ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).

Flammability: The propellants in ZORYVE foam are flammable. Avoid fire, flame, and smoking during and immediately following application.

The most common adverse reactions reported (≥1%) for ZORYVE cream 0.05% for pediatric patients with atopic dermatitis 2 to 5 years of age were upper respiratory tract infection (4.1%), diarrhea (2.5%), vomiting (2.1%), rhinitis (1.6%), conjunctivitis (1.4%), and headache (1.1%).

The most common adverse reactions reported (≥1%) for ZORYVE cream 0.15% for patients with atopic dermatitis 6 years of age or older were headache (2.9%), nausea (1.9%), application site pain (1.5%), diarrhea (1.5%), and vomiting (1.5%).

The most common adverse reactions reported (≥1%) for ZORYVE cream 0.3% for plaque psoriasis were diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%), application site pain (1.0%), upper respiratory tract infection (1.0%), and urinary tract infection (1.0%).

The most common adverse reactions reported (≥1%) for ZORYVE foam 0.3% for plaque psoriasis were headache (3.1%), diarrhea (2.5%), nausea (1.7%), and nasopharyngitis (1.3%).

The most common adverse reactions reported (≥1%) for ZORYVE foam 0.3% for seborrheic dermatitis were nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%).

Please see full Prescribing Information for ZORYVE cream and full Prescribing Information for ZORYVE foam.

INDICATIONS

ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age.

ZORYVE cream, 0.15%, is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older.

ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older.

ZORYVE topical foam, 0.3%, is indicated for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older.

ZORYVE topical foam, 0.3%, is indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.

References: 1. ZORYVE^® foam. Prescribing information. Arcutis Biotherapeutics, Inc; 2025. 2. ZORYVE^® cream. Prescribing information. Arcutis Biotherapeutics, Inc; 2025. 3. Osborne DW. Diethylene glycol monoethyl ether: an emerging solvent in topical dermatology products. J Cosmet Dermatol. 2011;10:325–329. 4. Osborne DW, Musakhanian J. Skin penetration and permeation properties of Transcutol^® - neat or diluted mixtures. AAPS PharmSciTech. 2018;19(8):3512–3533. 5. Berk D, Osborne DW. Krafft temperature of surfactants in vehicles for roflumilast and pimecrolimus cream and effects on skin tolerability. Poster presented at: The Society for Investigative Dermatology Annual Meeting; May 18–22, 2022; Portland, OR. 6. Björklund S, Pham QD, Jensen LB, et al. The effects of polar excipients transcutol and dexpanthenol on molecular mobility, permeability, and electrical impedance of the skin barrier. J Colloid Interface Sci. 2016;479:207–220. 7. Data on File. Arcutis Biotherapeutics, Inc.

ICD-10=International Classification of Diseases, Tenth Revision; IGA=Investigator Global Assessment.

References: 1. ZORYVE^® foam. Prescribing information. Arcutis Biotherapeutics, Inc; 2025. 2. ZORYVE^® cream. Prescribing information. Arcutis Biotherapeutics, Inc; 2024. 3. CMS.gov. 2025 ICD-10-CM. Centers for Medicare & Medicaid Services. Updated January 17, 2025. Accessed June 9, 2025. https://www.cms.gov/medicare/coding-billing/icd-10-codes 4. Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84(2):432-470. 5. Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 2023;89(1):e1-e20. 6. Clark GW, Pope SM, Jaboori KA. Diagnosis and treatment of seborrheic dermatitis. Am Fam Physician. 2015;91(3):185-190.

References: 1. ZORYVE^® cream. Prescribing information. Arcutis Biotherapeutics, Inc; 2025. 2. ZORYVE^® foam. Prescribing information. Arcutis Biotherapeutics, Inc; 2025.

References: 1. ZORYVE^® cream. Prescribing information. Arcutis Biotherapeutics, Inc; 2025. 2. ZORYVE^® foam. Prescribing information. Arcutis Biotherapeutics, Inc; 2025.

Legal Disclaimer Privacy Notice HCP Notice at Collection Consumer Health Data Privacy Policy Cookie Settings Contact Us

© 2025 Arcutis Biotherapeutics, Inc. All rights reserved.
US-COM-PTF-00395 v2.0 10/25US-COM-PTF-00839 v.20 10/25US-COM-154-00257 v2.0 10/25US-COM-PTF-00396 v2.0 10/25

IMPORTANT SAFETY INFORMATION
AND INDICATIONS

MORE

LESS

ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).

Flammability: The propellants in ZORYVE foam are flammable. Avoid fire, flame, and smoking during and immediately following application.

The most common adverse reactions reported (≥1%) for ZORYVE cream 0.05% for pediatric patients with atopic dermatitis 2 to 5 years of age were upper respiratory tract infection (4.1%), diarrhea (2.5%), vomiting (2.1%), rhinitis (1.6%), conjunctivitis (1.4%), and headache (1.1%).

The most common adverse reactions reported (≥1%) for ZORYVE cream 0.15% for patients with atopic dermatitis 6 years of age or older were headache (2.9%), nausea (1.9%), application site pain (1.5%), diarrhea (1.5%), and vomiting (1.5%).

The most common adverse reactions reported (≥1%) for ZORYVE cream 0.3% for plaque psoriasis were diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%), application site pain (1.0%), upper respiratory tract infection (1.0%), and urinary tract infection (1.0%).

The most common adverse reactions reported (≥1%) for ZORYVE foam 0.3% for plaque psoriasis were headache (3.1%), diarrhea (2.5%), nausea (1.7%), and nasopharyngitis (1.3%).

The most common adverse reactions reported (≥1%) for ZORYVE foam 0.3% for seborrheic dermatitis were nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%).

Please see full Prescribing Information for ZORYVE cream and full Prescribing Information for ZORYVE foam.

INDICATIONS

ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age.

ZORYVE cream, 0.15%, is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older.

ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older.

ZORYVE topical foam, 0.3%, is indicated for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older.

ZORYVE topical foam, 0.3%, is indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.

You are now leaving ZORYVEHCP.com.

Arcutis Biotherapeutics is not responsible for content on the site that you are about to enter. If you would like to continue, click OK.